绿叶制药：授予恩华和信三款抗精神病药长效针剂产品在中国大陆地区的独家商业化权利

Core Viewpoint - Recently, the company announced a collaboration agreement with Jiangsu Enhua and Xin Medical Marketing Co., Ltd., a subsidiary of Enhua Pharmaceutical, granting exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1 - The three products involved are Risperidone, Paliperidone, and Aripiprazole, all of which are used for the treatment of schizophrenia [1] - Enhua and Xin will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the company retains ownership of the assets, registration certificates, and all intellectual property rights [1] - The agreement has a duration of 10 years, with Enhua making a one-time non-refundable payment of $20 million for the licensing fee [1]